ArticleNanomedicine : nanotechnology, biology, and medicine2009
Renal vascular inflammation induced by Western diet in ApoE-null mice quantified by (19)F NMR of VCAM-1 targeted nanobeacons.
Article in Nanomedicine : nanotechnology, biology, and medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 63 citations in OpenAlex.
- TargetedImmunotherapy advances · 2026Review
- Histochemistry for Molecular Imaging in Nanomedicine.International journal of molecular sciences · 2024Review
- Nanotechnology as a Versatile Tool forPharmaceutics · 2022Review
- Nanoparticle theranostics in cardiovascular inflammation.Seminars in immunology · 2021Review
- Nanoparticles for "two color"Journal of colloid and interface science · 2020Article
- Single-Chain Variable Fragment Antibody of Vascular Cell Adhesion Molecule 1 as a Molecular Imaging Probe for Colitis Model Rabbit Investigation.Contrast media & molecular imaging · 2019Article
- Vascular targeting of nanoparticles for molecular imaging of diseased endothelium.Advanced drug delivery reviews · 2017Review
- Targeting and therapeutic peptides in nanomedicine for atherosclerosis.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- A bisphosphonate forJournal of fluorine chemistry · 2016Article
- Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis.Regenerative engineering and translational medicine · 2016Article
- Recent Advances inEngineering (Beijing, China) · 2015Article
- Inflammatory Stress Exacerbated Mesangial Foam Cell Formation and Renal Injury via Disrupting Cellular Cholesterol Homeostasis.Inflammation · 2015Article
- Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents.Nanomedicine (London, England) · 2015Review
- Targeted nanotechnology for cancer imaging.Advanced drug delivery reviews · 2014Review
- Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus.Nano letters · 2014Article
- Perfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent.Scientifica · 2014Review
- Perfluorocarbon nanoparticles for physiological and molecular imaging and therapy.Advances in chronic kidney disease · 2013Review
- Molecular imaging of inflammation in atherosclerosis.Theranostics · 2013Review
- New frontiers and developing applications in 19F NMR.Progress in nuclear magnetic resonance spectroscopy · 2013Review
- Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development.Circulation research · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
We have designed multifunctional nanoparticulate reporter bioprobes capable of targeting vascular cell adhesion molecule 1 (VCAM-1), which is up-regulated in numerous inflammatory processes. These perfluorocarbon-cored nanoparticles emit a unique (19)F magnetic resonance (MR) signature, providing the potential to localize and quantify VCAM-1 expression in early atherosclerosis. Nanoparticle-VCAM-1 targeting specificity was confirmed by in vitro binding and competition studies. ApoE-null and control C57-BL6 mice (n = 6/group), fed a Western diet for 35 weeks, were injected i.v. with targeted or non-targeted nanoparticles. After two hours, kidneys were excised and prepared for analysis. ApoE-null kidneys exhibited increased VCAM-1-targeted nanoparticle content over healthy controls by (19)F MR spectroscopy (36.5+8.8 vs. 9.3+2.2 x 10(8)/g, P < .05), which correlated with increased VCAM-1 staining (2.5 +/- 1.3% vs. 0.9 +/- 0.3%, P < .05); their relative biodistributions were confirmed by fluorescence microscopy and MR imaging. These molecular imaging agents offer new approaches for detection, quantification, and longitudinal evaluation of early inflammation utilising (19)F MR spectroscopy and imaging. FROM THE CLINICAL EDITOR: Multifunctional nanoparticulate reporter bioprobes capable of targeting vascular cell adhesion molecule 1 (VCAM-1) are reported in this paper. These perfluorocarbon-cored nanoparticles offer new approaches for detection, quantification, and longitudinal evaluation of early inflammation utilising 19F MR spectroscopy and imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.